Article Data

  • Views 1057
  • Dowloads 141

Original Research

Open Access

Efficacy and safety of immediate-release oxycodone combined with sustained-release oxycodone titration in opioid-tolerant patients with moderate to severe cancer pain

  • Shusheng Wu1,†
  • Jun Xie2,†
  • Gang Cheng3
  • Shunan Ding4
  • Wanping Li5
  • Yuliang Xu6
  • Xiaosi Chen7
  • Peng Xing8
  • Yifu He1,*,

1Department of Medical Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, 230031 Hefei, Anhui, China

2Lung Cancer Diagnosis and Treatment Center, Cancer Hospital of Anhui Huainan Oriental Hospital Group, 232035 Huainan, Anhui, China

3Department of Oncology, Bozhou People’s Hospital, 236000 Bozhou, Anhui, China

4Department of Medical Oncology, The Eighth People’s Hospital of Hefei, 238000 Hefei, Anhui, China

5Department of Medical Oncology, The People’s Hospital of Huaibei City, 235000 Huaibei, Anhui, China

6Department of Medical Oncology, Anhui Jimin Cancer Hospital, 230000 Hefei, Anhui, China

7Department of Oncology, Dangtu County People’s Hospital, 243000 Maanshan, Anhui, China

8Department of Oncology, Jingxian County Hospital, 242500 Xuancheng, Anhui, China

DOI: 10.22514/sv.2024.128 Vol.20,Issue 10,October 2024 pp.72-80

Submitted: 20 June 2024 Accepted: 20 August 2024

Published: 08 October 2024

*Corresponding Author(s): Yifu He E-mail: yifuhe@fsyy.ustc.edu.cn

† These authors contributed equally.

Abstract

This study aimed to evaluate the efficacy of immediate-release (IR) oxycodone in combination with sustained-release (SR) oxycodone titration for managing moderate-to-severe cancer pain in opioid-tolerant patients. Participants were selected based on a numerical rating scale (NRS) score of ≥4 and a daily oxycodone dose of ≥50 mg. IR oxycodone was administered orally as a rescue medication for breakthrough pain (BTP). Pain intensity scores, frequency of BTP, daily doses of SR and IR oxycodone, and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Patients with Advanced Cancer (EORTC QLQ-C15-PAL) scores were assessed over a three-day period. Adverse effects were also recorded. A total of 109 patients were enrolled in the study. Pain relief rates were 32% (35/109) on day 1, 44%(48/109) on day 2, and 67% (73/109) on day 3. Compared to baseline, the average NRS score decreased significantly on day 1 (p = 0.0030), day 2 (p < 0.0001), and day 3 (p < 0.0001). On day 1, 100% of patients experienced ≤2 BTP episodes per day, while 95%had ≤1 episode per day by day 3. There was a significant reduction in BTP episodes on days 2 and 3 compared to day 1 (p = 0.0187 and p < 0.0001, respectively). All eight EORTC QLQ-C15-PAL items showed significant improvements (p < 0.0100) from baseline. The incidence of adverse events was 42%. The combination of IR oxycodone with SR oxycodone titration is both feasible and tolerable for opioid-tolerant patients with moderate-to-severe cancer pain.


Keywords

Cancer pain; Oxycodone; Immediate-release; Titration; Efficacy


Cite and Share

Shusheng Wu,Jun Xie,Gang Cheng,Shunan Ding,Wanping Li,Yuliang Xu,Xiaosi Chen,Peng Xing,Yifu He. Efficacy and safety of immediate-release oxycodone combined with sustained-release oxycodone titration in opioid-tolerant patients with moderate to severe cancer pain. Signa Vitae. 2024. 20(10);72-80.

References

[1] Snijders RAH, Brom L, Theunissen M, van den Beuken-van Everdingen MHJ. Update on prevalence of pain in patients with cancer 2022: a systematic literature review and meta-analysis. Cancers. 2023; 15: 591.

[2] van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. Journal of Pain and Symptom Management. 2016; 51: 1070–1090.e9.

[3] Mercadante S. Opioid dose titration for cancer pain. European Journal of Pain. 2024; 28: 359–368.

[4] Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. The Lancet Oncology. 2012; 13: e58–e68.

[5] Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M, et al. Management of cancer pain in adult patients: ESMO clinical practice guidelines. Annals of Oncology. 2018; 29: iv166–iv191.

[6] Huang HX, Liu KK, Zhang L, Huang YM, Liu WH, Xiao J. Influencing factors of end-of-dose failure in patients with cancer pain after oral oxycodone sustained-release tablets: a retrospective, case-control study. Japanese Journal of Clinical Oncology. 2021; 51: 932–941.

[7] Løhre ET, Jakobsen G, Solheim TS, Klepstad P, Thronæs M. Breakthrough and episodic cancer pain from a palliative care perspective. Current Oncology. 2023; 30: 10249–10259.

[8] Bossi P, Pietrzyńska T, Margarit Ferri C, Mansilla I, Tellone V, Fioravanti S, et al. Compliance with the breakthrough cancer pain European guidelines and impact on patients’ quality of life: an observational prospective study. Frontiers in Pain Research. 2024; 5: 1388837.

[9] Crawford GB, Lakhani A, Palmer L, Sebalj M, Rolan P. A systematic review of qualitative research exploring patient and health professional perspectives of breakthrough cancer pain. Supportive Care in Cancer. 2023; 31: 619.

[10] Zhao S, Xu C, Lin R. Controlled release of oxycodone as an opioid titration for cancer pain relief: a retrospective study. Medical Science Monitor. 2020; 26: e920598.

[11] Rahmadi M, Madina U, Sulianto I, Padolo E, Ardianto C, Ratri DMN, et al. Study on dosage range evaluation opioid analgesic for breakthrough pain in cancer patients: a retrospective study. Annals of Palliative Medicine. 2021; 10: 1237–1243.

[12] Yu Y, Zhang P, Chen D, Jiang SF. Knowledge and practice of the management of breakthrough cancer pain among general practitioners providing palliative care in Shanghai, China: a cross-sectional survey. BMJ Open. 2023; 13: e073670.

[13] Mercadante S, Maltoni M, Russo D, Adile C, Ferrera P, Rossi R, et al. The prevalence and characteristics of breakthrough cancer pain in patients receiving low doses of opioids for background pain. Cancers. 2021; 13: 1058.

[14] Mercadante S. Once again... breakthrough cancer pain: an updated overview. Journal of Anesthesia, Analgesia and Critical Care. 2023; 3: 23.

[15] Mercadante S. The use of parenteral opioids in cancer pain management. Cancers. 2023; 15: 3778.

[16] Sadiq NM, Dice TJ, Mead T. Oxycodone. StatPearls Publishing: Treasure Island (FL). 2024.

[17] Drugs and Lactation Database (LactMed®). Oxycodone. National Institute of Child Health and Human Development: Bethesda (MD). 2006.

[18] Staahl C, Christrup LL, Andersen SD, Arendt-Nielsen L, Drewes AM. A comparative study of oxycodone and morphine in a multi-modal, tissue-differentiated experimental pain model. Pain. 2006; 123: 28–36.

[19] Wang J, Yuan X, Guo W, Xiang X, Wu Q, Fang M, et al. Sedation and analgesia for liver cancer percutaneous radiofrequency ablation: fentanyl and oxycodone comparison. International Journal of Medical Sciences. 2020; 17: 2194–2199.

[20] Wan Z, Chu C, Zhou R, Que B. Effects of oxycodone combined with flurbiprofen axetil on postoperative analgesia and immune function in patients undergoing radical resection of colorectal cancer. Clinical Pharmacology in Drug Development. 2021; 10: 251–259.

[21] McDonald AM, Spencer SA, Willey CD, Bonner JA, Dobelbower MC, Swain TA, et al. Lipid microsphere bound oxycodone for pain management in patients receiving radiotherapy for head and neck cancer. Support Care Cancer. 2021; 29: 263–269.

[22] Cuomo A. Fentanyl in cancer pain management: avoiding hasty judgments and discerning its potential benefits. Drugs in Context. 2023; 12: 2023-10-2.

[23] Daeninck P, Gagnon B, Gallagher R, Henderson JD, Shir Y, Zimmermann C, et al. Canadian recommendations for the management of breakthrough cancer pain. Current Oncology. 2016; 23: 96–108.

[24] Baek SK, Kim DY, Kang SY, Sym SJ, Kim YS, Lee JY. A Korean nationwide survey for breakthrough cancer pain in an inpatient setting. Cancer Research and Treatment. 2016; 48: 768–774.

[25] Swarm RA, Paice JA, Anghelescu DL, Are M, Bruce JY, Buga S, et al. Adult cancer pain, version 3.2019, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2019; 17: 977–1007.

[26] Liang J, Chen L, Yang S, Zhang H, Li L, Chen Z, et al. A 12-hour rapid titration method for cancer pain: a randomized, controlled, open-label study. Annals of Palliative Medicine. 2021; 10: 88–96.

[27] Lee KH, Kang JH, Oh HS, Choi MK, Shim BY, Eum YJ, et al. Intravenous oxycodone versus intravenous morphine in cancer pain: a randomized, open-label, parallel-group, active-control study. Pain Research and Management. 2017; 2017: 9741729.

[28] Pilz MJ, Aaronson NK, Arraras JI, Caocci G, Efficace F, Groenvold M, et al. Evaluating the thresholds for clinical importance of the EORTC QLQ-C15-PAL in patients receiving palliative treatment. Journal of Palliative Medicine. 2021; 24: 397–404.

[29] Matsumura C, Yamada M, Jimaru Y, Ueno R, Takahashi K, Yano Y. Relationship between Pain Scores and EORTC QLQ-C15-PAL scores in outpatients with cancer pain receiving opioid therapy. Biological and Pharmaceutical Bulletin. 2021; 44: 357–362.

[30] Samolsky Dekel BG, Tomasi M, Vasarri A, Gori A, Adversi M, Castagnoli A, et al. Opioid titration with sustained-release oxycodone and immediate-release morphine for moderate/severe cancer pain: a pilot assessment of the CoDem protocol. Journal of Opioid Management. 2014; 10: 29–38.

[31] Zhou J, Wang Y, Jiang G. Oxycodone versus morphine for cancer pain titration: a systematic review and pharmacoeconomic evaluation. PLOS ONE. 2020; 15: e0231763.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.

Index Copernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.

Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.

Scopus: CiteScore 1.3 (2023) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.

Submission Turnaround Time

Conferences

Top